Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib (HM43239) for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Join Us
    • Values & Culture
    • Perks & Benefits
    • Explore Careers
  • Contact

Press Releases

News

News

  • Press Releases
  • Presentations
  • Events

Aptose to Present at the Cantor Global Healthcare Conference

Sep 18, 2023 7:45am EDT

Aptose to Present at the Cantor Global Healthcare Conference

Sep 18, 2023 7:45am EDT

Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical

Sep 06, 2023 7:45am EDT

Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical

Sep 06, 2023 7:45am EDT

Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 24, 2023 7:30am EDT

Aptose Reports Results for the Second Quarter 2023

Aug 10, 2023 4:02pm EDT

Aptose to Report Second Quarter 2023 Financial Results andĀ Hold Conference Call on Thursday, August 10, 2023

Jul 27, 2023 4:04pm EDT

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Jun 26, 2023 4:05pm EDT

Aptose Presents Highlights from Clinical Update

Jun 10, 2023 12:00pm EDT

Aptose Biosciences Provides Update on Reverse Stock Split

Jun 05, 2023 7:30am EDT
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...27
Next
© 2023 Aptose Biosciences Inc. All Rights Reserved.
Privacy Policy Clinical Trials Policy Disclaimer Sitemap Manage Cookie Preferences